Termedia.pl
 
 
ISSN: 1505-8409
Przewodnik Lekarza/Guide for GPs
Current issue Archive About the journal Supplements Contact Instructions for authors
3/2009
vol. 12
 
Share:
Share:
more
 
 
abstract:

ACE inhibitors and sartans – why should they not be prescribed together?

Piotr Jankowski
,
Danuta Czarnecka

Przew Lek 2009; 3: 46-49
Online publish date: 2009/08/03
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Combination treatment of hypertension has been prescribed more and more frequently in recent years. The blood pressure lowering effect is greater and side effects are less pronounced when agents acting on various systems are combined. Unfortunately, this condition is not fulfilled when an ACE inhibitor is combined with a sartan. Both drugs suppress the renin-angiotensin system therefore their combination is not very effective (in respect of blood pressure reduction) and leads to higher risk of side effects because most side effects are not counteracted, but rather augmented by the other agent (for instance both agents increase the potassium level). Indeed, the ONTARGET trial proved that in patients with symptomatic atherosclerosis or diabetes, but without heart failure combination treatment with an ACE inhibitor and a sartan is not related to any benefit when compared with monotherapy, but leads to more side effects. However, it should be underlined that these findings do not preclude the combination of an ACE inhibitor and a sartan in heart failure patients or those with resistant hypertension.
keywords:

hypertension, ACE inhibitor, sartan

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe